Peptides9 min read
GHK-Cu and hair growth: what an eyebrow study can tell us
A small eyebrow trial offers an early GHK-Cu finding. Here is what it measured and why scalp hair loss needs its own evidence.
Read articleBlog
Research, explained. Explore peptides, supplements, hormone health, longevity and red light therapy with clear, practical breakdowns of what the studies actually tell us.
Peptides articles
All articlesMetabolism, recovery and emerging research
Peptides9 min read
CJC-1295 raises GH and IGF-1: what does that mean for health?
The original CJC-1295 studies measured sustained hormone responses. Learn what those findings establish and why health benefits need direct testing.
Read article
Peptides8 min read
Can ipamorelin trial safety be applied to long-term use?
Brief intravenous studies cannot establish chronic subcutaneous safety. Learn what the surgical trial reported and why duration, formulation and attribution matter.
Read article
Peptides9 min read
Sermorelin and healthy aging: which evidence applies to whom?
Pediatric growth trials, short hormone studies and cognitive findings answer different questions. Here is what sermorelin research can tell older adults.
Read article
Peptides8 min read
IGF-1 LR3 and low blood sugar: what the evidence supports
Glucose lowering is a credible LR3 hazard, but animal experiments and related medicines do not define a safe human schedule.
Read article
Peptides8 min read
DSIP for withdrawal symptoms: why this is not an insomnia treatment claim
The historical DSIP withdrawal studies measured a different problem from chronic insomnia, with important gaps in comparison groups and follow-up.
Read article
Peptides9 min read
MOTS-c and CB4211: two names that should not share one evidence column
CB4211 produced exploratory human biomarker findings, but it is a MOTS-c analogue with its own formulation history. Its trial cannot validate native MOTS-c.
Read article
Peptides9 min read
SS-31 and primary mitochondrial disease: why diagnosis changes applicability
Elamipretide's myopathy trials, genetic subgroup findings and Barth syndrome approval answer different questions. Diagnosis determines how the evidence applies.
Read article
Peptides9 min read
Epitalon versus epithalamin: why the name changes the evidence
Why older epithalamin longevity reports cannot be treated as trials of synthetic Epitalon, and what the cell and animal research actually adds.
Read article
Peptides9 min read
Eloralintide and nausea: what receptor selectivity can—and can't—tell us
Early nausea rates were low, but the larger trial showed substantial variation. Receptor selectivity is only one possible part of the explanation.
Read article
Peptides9 min read
SS-31 and macular degeneration: what the eye trials actually found
Elamipretide eye trials separate visual performance from retinal imaging. Here is what ReCLAIM found, what it missed and what patients can ask.
Read article
Peptides9 min read
Kisspeptin and hormonal feedback: why more is not a simple equation
Kisspeptin can raise reproductive hormones, but timing, feedback and repeated exposure change the response. Human studies explain why more is not always more.
Read article109–120 of 323 articles